ESMO Congress 2026Developing

telisotuzumab

4 reports3 sourcesupdated 16 hours ago

Start here

Report excerpt

The 2026 WCLC ES06 session brought together four presentations reviewing research progress on lung cancer biomarkers from four angles: omics-based classification, spatial omics and AI, ADC target protein expression, and cytology-based triage.

Excerpted from mp.weixin.qq.com

Coverage timeline

Follow the coverage to see the different angles.

Oct 24

20:45
x.com
📢 #ESMO26 concomitant paper: A randomized phase I study of telisotuzumab adizutecan (ABBV-400, Temab-A) in combination with bevacizumab versus trifluridine-tipiracil with bevacizum
15:45
x.com
#ESMO26 Dr. David Sommerhalder presents OS from M21-404: telisotuzumab adizutecan (Temab-A), a c-MET directed ADC with a topo-1 payload. mPFS 6.8m OS 13.8m in EGFR wild type. mPFS

Oct 22

18:00
mp.weixin.qq.com
2026 WCLC ES06 Session: Lung Cancer Biomarkers Move From Immunohistochemistry to Omics and AI
The 2026 WCLC ES06 session brought together four presentations reviewing research progress on lung cancer biomarkers from four angles: omics-based classification, spatial omics and AI, ADC target protein expression, and cytology-based triage.

Oct 14

20:00
clinicaltrials.gov
Phase II Study to Evaluate Telisotuzumab Adizutecan in Combination With RC148 as First-Line Treatment for Patients With Non-Squamous Non-Small-Cell Lung Cancer

Heat trend for this story

Heat now 14·Peak in the comparable set 21 (Oct 24 21:00)·Change over 24h in the comparable set +350%·Participants now 3

Participants counted3

Heat over time

Participants counted above, heat below. The trend compares only the participants observed in full throughout, so its set can be smaller than the heat figure itself. Move the pointer or click the chart for an hour's reading; the left and right arrow keys work too.